MRK
Merck & Co., Inc.$117.09
Sell
Target $99.63
Report: Mar 11, 2026Healthcare • Drug Manufacturers - General • Mature CompounderSnapshot
Decision-first overview with recommendation, valuation anchor, and current setup.
Company Overview
Research Snapshot
Price History
Pelican View
Current$117.09-14.9%
Rec: SellConviction: High
Entry Target
N/A
N/A
Fair Value
$99.63
(15% below current)
Stop Loss
N/A
N/A
Position Size
None
Time Horizon
N/A
Key Metrics
Live Snapshot
Market Data
52 Week High$125.14
52 Week Low$73.31
Avg. 3 Month Volume11.93M
Efficiency
LTM Gross Margin74.8%
LTM EBITDA Margin43.5%
LTM EBIT Margin34.5%
LTM Operating Margin32.6%
LTM ROA14.6%
LTM ROE36.2%
LTM ROIC26.1%
LTM ROCE23.4%
Capital Structure
Market Cap (MM)$297.4B
Enterprise Value (MM)$332.2B
Shares Outstanding2.48B
Total Debt (MM)$49.34B
Cash & Equivalents (MM)$14.56B
LTM Net Debt (MM)$34.77B
LTM Net Debt/EBITDA1.2x
Growth
TTM Rev. Growth1.3%
Last 3-Yr Rev. CAGR3.1%
Last 3-Yr EBITDA CAGR9.9%
Last 3-Yr EPS CAGR8.5%
Valuation
Street Target Price$128.54
LTM EV/Revenue5.1x
LTM EV/Gross Profit6.8x
LTM EV/EBIT14.8x
LTM EV/EBITDA11.8x
LTM P/E16.3x
LTM EV/FCF26.9x
LTM P/FCF24.1x
LTM P/TB3.4x
LTM P/B5.7x
Dividend Yield2.7%
Payout Ratio44.9%
Executive SummarySituation: Current price is $117.09 versus fair value $99.63 (-14.9% expected return), and valuation confidence is stable. Debate: Bull case depends on Winrevair commercial trajectory validation. Bear case centers on Keytruda Loss-of-Exclusivity (LOE). Conclusion: Recommendation is Sell with no position, pending a materially better risk/reward setup.
Bull Case
The bull case rests on the successful commercialization of Winrevair as a multi-billion dollar PAH franchise and the potential for the 70 billion dollar pipeline to exceed market expectations. Additionally, the Animal Health segment's high-margin stability could provide a valuation floor if the human pharma business faces temporary setbacks.
Bear Case
The bear case centers on the 2028 Keytruda patent cliff and the 0.4x M&A effectiveness ratio, which suggests that Merck is overpaying for growth that may not materialize in time. Furthermore, the 1.5 percentage point contraction in gross margins and persistent Gardasil weakness in China indicate that organic growth is insufficient to offset rising input costs and competitive pressures.
Key Catalysts
Mid-Term (6-18 months)Impact: High
Winrevair commercial trajectory validation. Achieving net sales of over 500 million dollars in FY2026 would validate the PAH franchise as a...
Near-Term (0-6 months)Impact: Moderate
Gardasil China recovery. A resumption of shipments to China and a reduction in channel inventory would signal a return to growth for the vac...
Long-Term (18+ months)Impact: Moderate
Merck is at a critical juncture as it integrates the 9 billion dollar Sidera acquisition and attempts to prove its $70B pipeline narrative a...
Primary Risks
Concern: High
Keytruda Loss-of-Exclusivity (LOE). The 2028 patent cliff for Keytruda, which represents 45% of sales, could lead to a permanent impairment...
Concern: Medium
M&A Execution and Overpayment. The company's reliance on high-priced acquisitions to fill the revenue hole could lead to further capital des...
Concern: Medium
The stewardship verdict is cautious. While the board features elite capital allocation expertise, including former CEOs of Ecolab and 3M, th...
Recent Activity
2025-04-10Market Movement
-5.32%Market/Sector Move -5.32%
2025-02-04SEC Filing (SC 13G/A)
-9.07%Merck & Co. files Schedule 13G/A reporting 19.96% beneficial ownership of Evaxion Biotech A/S shares
2024-07-30SEC Filing (8-K)
-9.81%Merck reports Q2 2024 sales of $16.1B, up 7% YoY, with KEYTRUDA sales growing 16% to $7.3B
2021-10-28SEC Filing (8-K)
+6.14%Merck reports Q3 2021 sales of $13.2B, up 20% YoY, with KEYTRUDA sales growing 22% to $4.5B
Valuation Table
9.8/10Decision Grade